But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

Evotec has inked a deal to sell its biologics manufacturing facility in Toulouse, France, to generics giant Sandoz for around ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s expectations. | Bristol Myers Squibb had a strong quarter, with key drugs old ...

The first commercial for Johnson & Johnson and Legend Biotech’s Carvykti focuses on the numbers that make up a multiple ...

As Celltrion looks to ward off potential import tariffs, the South Korean company’s odds of acquiring a large-scale drug ...

Takeda, coming off a high of 2024 growth, is pushing through what it says will be the worst of its Vyvanse-related declines.

Freshly appointed Center for Drug Evaluation and Research (CDER) leader George Tidmarsh M.D., Ph.D., will now take on the role of acting director of CBER as well, according to an internal letter from ...

Vinay Prasad, M.D., has left the FDA less than three months into the role as director of the Center for Biologics Evaluation ...

Teva’s chief drug Austedo—approved in Huntington’s disease and tardive dyskinesia—grew sales 19% to $498 million for the ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...